Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04384497

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study

Sponsor: Danderyd Hospital

Conditions COVID-19

Interventions SARS-CoV-2 convalescent plasma

Updated 5 times since 2020 Last updated: Dec 2, 2021 Started: May 7, 2020 Primary completion: Jun 1, 2020 Completion: Dec 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates COVID-19 and is currently completed. Danderyd Hospital leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

Status: Recruiting → Completed
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danderyd Hospital
Joakim Dillner
Karolinska Institutet
Karolinska University Hospital

Data source: Karolinska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Danderyd, Sweden
• Stockholm, Sweden